Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults*

References

• Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015;38:316–22.
   PubMed Web of Science ®Google Scholar
• Heller SR, Frier BM, Hersløv ML, Gundgaard J, Gough SC. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. Diabet Med. 2016;33:471–7.
   PubMed Web of Science ®Google Scholar
• Geller AI, Shehab N, Lovegrove MC, Kegler SR, Weidenbach KN, Ryan GJ, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med. 2014;174:678–86.
   PubMed Web of Science ®Google Scholar
• UK Hypoglycemia Study Group. Risk of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–7.
   PubMed Web of Science ®Google Scholar
• Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes. 1994; 43:403–10.
   PubMed Web of Science ®Google Scholar
• Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study. Pharmacoepidemiol Drug Saf. 2013;22:1326–35.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ. 2014;349:g5459.
   PubMed Web of Science ®Google Scholar
• Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81:184–9.
   PubMed Web of Science ®Google Scholar
• Brookhart MA, Wyss R, Layton JB, Stürmer T. Propensity score methods for confounding control in non-experimental research. Circ Cardiovasc Qual Outcomes. 2013;6:604–11.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2013; Vienna, Austria. Available from: http://www.R-project.org/
   Google Scholar
• Gordon J, Pockett RD, Tetlow AP, McEwan P, Home PD. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract. 2010; 64:1609–18.
   PubMed Web of Science ®Google Scholar
• Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997–2012. Diabetes Care. 2014;37:985–92.
   PubMed Web of Science ®Google Scholar
• Livingstone SJ, Levin D, Looker Lindsay RS, Wild SH, Joss N, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA. 2015;313:37–44.
   PubMed Web of Science ®Google Scholar
• Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011; 343:d4169.
   PubMed Web of Science ®Google Scholar
• Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009;53:298–304.
   PubMed Web of Science ®Google Scholar
• Strandberg AY, Hoti FJ, Strandberg TE, Christopher S, Haukka J, Korhonen P. All-cause and cause-specific mortality among users of basal insulins NPH, detemir, and glargine. PLoS One. 2016;11:e0151910.
   Google Scholar
• Rys P, Wojciechowski P, Rogoz-Sitek A, Niesyczyński G, Lis J, Syta A, et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetologica. 2015;54:649–62.
   Web of Science ®Google Scholar
• Wang L, Wei W, Miao R, Xie L, Baser O. Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study. BMJ Open. 2013;3:4e002348.
   Web of Science ®Google Scholar
• Davis KL, Tangirala M, Meyers JL, Wei W. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy. Curr Med Res Opin. 2013;29:1083–91.
   PubMed Web of Science ®Google Scholar
• Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt DA, Clarke WI. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care. 1998; 21:1870–5.
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med. 2005;22:749–55.
   PubMed Web of Science ®Google Scholar